Introduction to Mounjaro
Mounjaro (tirzepatide) is a groundbreaking medication developed by Eli Lilly and Company, primarily designed for the treatment of type 2 diabetes. Approved by the FDA in May 2022, Mounjaro represents a new class of drugs known as dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonists. This innovative approach not only helps in managing blood sugar levels but also offers potential benefits for weight management.
Mechanism of Action
Mounjaro works by mimicking the effects of two hormones that play a critical role in glucose metabolism:
1. GIP (Glucose-Dependent Insulinotropic Polypeptide): Stimulates insulin secretion in response to food intake while also inhibiting glucagon secretion, helping to lower blood glucose levels.
2. GLP-1 (Glucagon-Like Peptide-1): Enhances insulin secretion, slows gastric emptying, and promotes satiety, contributing to weight loss.
By activating both pathways, Mounjaro offers a multifaceted approach to diabetes management, improving glycemic control and aiding in weight reduction.